Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 170Neoplasms 129Prostatic Neoplasms 92Lung Neoplasms 82Colorectal Neoplasms 80Pancreatic Neoplasms 38Leiomyoma 37Carcinoma, Hepatocellular 36Lymphoma, Follicular 35Carcinoma, Non-Small-Cell Lung 31Neoplasm Metastasis 27Skin Neoplasms 26Liver Neoplasms 26Colonic Neoplasms 26Uterine Cervical Neoplasms 25Multiple Myeloma 23Glioblastoma 22Head and Neck Neoplasms 21Barrett Esophagus 21Polycystic Ovary Syndrome 19Brain Neoplasms 18Urinary Bladder Neoplasms 17Polyps 16Ovarian Neoplasms 15Esophageal Neoplasms 15Stomach Neoplasms 14Squamous Cell Carcinoma of Head and Neck 14Rectal Neoplasms 14Carcinoma, Squamous Cell 14Carcinoma, Basal Cell 14

Interventions

aflutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × INDUSTRY × Advanced NSCLC × Clear all
NCT03127449 2025-04-03

AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Allist Pharmaceuticals, Inc.

Phase NA Terminated
116 enrolled
Thoracic

Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡